• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ProQR Therapeutics N.V. - Ordinary Shares (NQ:PRQR)

    1.385 -0.055 (-3.82%)
    Delayed Quote Updated: 12:48 PM EDT, Oct 30, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about ProQR Therapeutics N.V. - Ordinary Shares

    < Previous 1 2 3 4 5 Next >
    News headline image
    Stocks That Hit 52-Week Lows On Wednesday ↗
    On Wednesday, 115 companies reached new 52-week lows. Noteworthy Points From Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low... 
    Via Benzinga
    News headline image
    Stocks That Hit 52-Week Lows On Monday ↗
    During Monday's session, 291 companies made new 52-week lows. Also check out this: Insiders Buying These 4 Penny Stocks Noteable 52-Week Lows And Highs: SAP (... 
    Via Benzinga
    News headline image
    Where ProQR Therapeutics Stands With Analysts ↗
    Analysts have provided the following ratings for ProQR Therapeutics (NASDAQ:PRQR) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... 
    Via Benzinga
    News headline image
    Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2022 ↗
    Upgrades According to Mizuho, the prior rating for Murphy Oil Corp (NYSE:MUR) was changed from Neutral to Buy. In the fourth quarter, Murphy Oil showed an EPS of $0.40,... 
    Via Benzinga
    News headline image
    Mid-Afternoon Market Update: US Stocks Extend Losses; Dow Tumbles 450 Points ↗
    US stocks extended losses toward the end of trading session, with the Dow Jones tumbling 450 points on Friday. 
    Via Benzinga
    News headline image
    78 Biggest Movers From Friday ↗
    Gainers Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) surged 26% to close at $2.24. Y-mAbs reported completion of pre-BLA meeting with the FDA for Omburtamab. China Online Education... 
    Via Benzinga
    News headline image
    Mid-Day Market Update: Nasdaq Drops 100 Points; Bloom Energy Shares Jump ↗
    The Nasdaq turned lower during the mid-day session, with the tech-laden index falling 100 points on Friday. 
    Via Benzinga
    News headline image
    52 Weeks High And Low Article ↗
    On Friday, 106 companies reached new 52-week lows. Things to Consider About Today's 52-Week Lows: Air Products & Chemicals (NYSE:APD) is the largest company... 
    Via Benzinga
    News headline image
    41 Stocks Moving In Friday's Mid-Day Session ↗
    Gainers Modular Medical, Inc. (NASDAQ: MODD) shares climbed 34.5% to $4.99 following its recent uplisting to the Nasdaq Capital Market on Thursday. Kaival Brands Innovations... 
    Via Benzinga
    News headline image
    Mid-Morning Market Update: Markets Open Higher As Dow Rises Over 100 Points ↗
    U.S. stocks opened on a strong note on Friday, after recording sharp losses in the previous session. 
    Via Benzinga
    News headline image
    The Daily Biotech Pulse: Adcom Recommends Additional Trials For Lilly's Partnered Cancer Drug, Novavax Touts Pediatric Vaccine Data, TC Biopharm IPO ↗
    Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adcom Rules That Lilly May Have To Conduct Additional Studies For Co-... 
    Via Benzinga
    News headline image
    ProQR Shares Crater After Disappointing Sepofarsen Data In Inherited Vision Loss Disorder ↗
    ProQR Therapeutics N.V. (NASDAQ: PRQR) shares are plunging after disappointing data from its pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated... 
    Via Benzinga
    News headline image
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
    Rise and shine, trader! We're starting off another day of investing with a breakdown of the biggest pre-market stock movers for Tuesday! 
    Via InvestorPlace
    News headline image
    16 Stocks Moving in Tuesday's Pre-Market Session ↗
    Gainers ObsEva SA (NASDAQ: OBSV) rose 22.2% to $1.87 in pre-market trading after the company announced a corporate update, including an increase in share capital on... 
    Via Benzinga
    News headline image
    The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings ↗
    Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Roche's Spark Subsidiary Reports Positive Phase 1/2 Data For Hemophilia... 
    Via Benzinga
    News headline image
    The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More ↗
    Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at... 
    Via Benzinga
    News headline image
    Here's Why ProQR Stock Surged on Thursday ↗
    A new collaboration deal with Eli Lilly could be worth up to $1.3 billion. 
    Via The Motley Fool
    News headline image
    Why ProQR Therapeutics's Stock Is Trading Higher Today ↗
    ProQR Therapeutics's (NASDAQ:PRQR) shares are trading higher after the company announced Axiomer RNA editing licensing and research collaboration with Lilly. ProQR... 
    Via Benzinga
    News headline image
    48 Biggest Movers From Yesterday ↗
    Gainers Rocket Lab USA, Inc. (NASDAQ: RKLB) jumped 37.3% to settle at $20.72. Rocket Lab reported 1H sales of $29.5 million and announced it has been awarded a contract to deploy... 
    Via Benzinga
    News headline image
    35 Stocks Moving In Thursday's Mid-Day Session ↗
    Gainers Gevo, Inc. (NASDAQ: GEVO) shares climbed 36.6% to $7.91. Chevron and Gevo announced intent to pursue sustainable aviation fuel investment. Offerpad Solutions Inc (NYSE:... 
    Via Benzinga
    News headline image
    The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization ↗
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:... 
    Via Benzinga
    News headline image
    Eli Lilly Inks Another RNA Collab, This Time With ProQR ↗
    Eli Lilly And Co (NYSE: LLY) is doubling down on RNA research as it pens another pact with a quiet RNA editing player focused on neuroscience, ProQR... 
    Via Benzinga
    News headline image
    21 Stocks Moving in Thursday's Pre-Market Session ↗
    Gainers Cardiff Oncology, Inc. (NASDAQ: CRDF) rose 17.3% to $8.27 in pre-market trading after the company announced new data from its Phase 1b/2 trial in KRAS-mutated metastatic... 
    Via Benzinga
    News headline image
    ProQR Therapeutics Stock Is Trading Higher On Antisense Oligonucleotide Development Pact ↗
    Yarrow Biotechnology Inc, a newly created company by RTW Investments LP, has in-licensed exclusive rights to ProQR Therapeutics N.V.'s (NASDAQ: ... 
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
    Gainers BioLine Rx (NASDAQ:BLRX) shares moved upwards by 65.2% to $5.27 during Tuesday's pre-market session. The market value of their outstanding shares is at $226.7... 
    Via Benzinga
    News headline image
    An End to This Rare Syndrome Could Be an Opportunity for Investors ↗
    A rare genetic disease that causes combined blindness and deafness may have a novel treatment in line after positive phase 1/2 trial results last month. 
    Via The Motley Fool
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.